TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Satellite Symposium | Sequencing treatment options in primary refractory DLBCL

Featured:

Andrew DaviesAndrew Davies

Jun 25, 2021


The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia. Professor Andrew Davies, University of Southampton, Southampton, UK, discusses how to treat a patient with primary refractory diffuse large B-cell lymphoma (DLBCL).

Sequencing treatment options in primary refractory DLBCL

Davies begins by outlining a specific patient case, caveats in the current treatment options for DLBCL, and the patterns of primary refractory DLBCL. The presentation then moves on to highlight the role of transplant in the DLBCL patient population, and introduces emerging therapeutics such as CAR T-cell therapy and novel treatment combination regimens.

Satellite Symposium | Sequencing treatment options in primary refractory DLBCL

If you would like to download the slides from Andrew Davies' presentation, click below.